Gene Panel Market By Type of Panel (Targeted Gene Panels, Whole Exome Sequencing Panels, Custom Gene Panels, Cancer Gene Panels, Genetic Disorder Panels), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray-Based, Sanger Sequencing), By Application Area (Diagnostics, Research, Companion Diagnostics, Personalized Medicine), By End-User (Hospitals, Clinical Laboratories, Research Institutions, Biopharmaceutical Companies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Gene Panel Market was valued at USD 4.2 billion in 2023 and will surpass USD 6.7 billion by 2030; growing at a CAGR of 7.1% during 2024 - 2030.

The gene panel market is experiencing substantial growth as advancements in genetic testing and personalized medicine continue to reshape the healthcare landscape. Gene panels allow for the efficient analysis of multiple genes associated with specific diseases or conditions, enabling clinicians to make more accurate diagnoses and tailor treatments to individual patients. This technology has become integral in diagnosing genetic disorders, identifying cancer-related mutations, and guiding the development of personalized medicine. As the demand for genetic testing rises, fueled by the growing awareness of personalized healthcare and precision medicine, the gene panel market is expected to continue expanding.

The increasing prevalence of genetic disorders, the rising incidence of cancer, and the need for more precise diagnostic tools are driving the market's growth. Advances in sequencing technologies, such as next-generation sequencing (NGS), have made genetic testing faster, more affordable, and more accessible, which further accelerates the adoption of gene panels. Additionally, the shift toward personalized medicine and companion diagnostics is fueling demand for gene panels in clinical settings. The market is also bolstered by ongoing research in genomics, which is unlocking new insights into the genetic basis of diseases and opening opportunities for new therapeutic approaches.

Next-Generation Sequencing Panels Lead the Gene Panel Market

Next-generation sequencing (NGS) panels are the largest and most widely used technology in the gene panel market, due to their high throughput, accuracy, and ability to analyze large numbers of genes simultaneously. NGS technology enables researchers and clinicians to decode the entire genome or specific subsets of genes quickly and cost-effectively, making it ideal for applications in diagnostics, cancer research, and personalized medicine. NGS gene panels can assess various genetic mutations associated with cancer, genetic disorders, and other diseases, providing critical information for patient care and treatment decisions.

The widespread adoption of NGS panels is driven by their ability to provide comprehensive insights into a patient’s genetic makeup, enabling precise and personalized treatment plans. As the technology continues to evolve, the accuracy, sensitivity, and cost-efficiency of NGS panels improve, making them the go-to solution in genetic testing. NGS panels are particularly crucial in oncology for identifying genetic mutations associated with various types of cancers, guiding targeted therapies, and monitoring treatment progress. With advancements in sequencing technology and the growing demand for personalized medicine, NGS panels are expected to maintain their dominance in the market.

Cancer Gene Panels Are the Fastest Growing Segment

Cancer gene panels represent the fastest-growing segment in the gene panel market, driven by the rising incidence of cancer worldwide and the increasing focus on personalized oncology. These panels are designed to detect genetic mutations in specific genes linked to various types of cancer, allowing for early diagnosis, prognosis prediction, and targeted treatment strategies. Cancer gene panels can help identify genetic alterations that drive tumor growth, guiding the selection of therapies that are more likely to be effective based on the patient’s genetic profile.

The demand for cancer gene panels is increasing as the importance of precision medicine in oncology continues to gain recognition. These panels are being widely used in clinical settings to identify mutations in genes such as BRCA1, BRCA2, and EGFR, among others, which play a critical role in cancer development and treatment response. The rapid growth of cancer gene panels is fueled by advancements in sequencing technology, the development of targeted therapies, and the increasing awareness of the need for personalized approaches to cancer care. As more cancer gene panels become commercially available and clinical evidence supporting their use grows, the segment is expected to experience continued rapid growth.

Hospitals Are the Leading End-User Segment

Hospitals represent the leading end-user segment in the gene panel market, owing to their central role in patient care, diagnosis, and treatment. Hospitals serve as the primary setting for the administration of gene panel tests, particularly in the areas of genetic disorder diagnosis, cancer screening, and personalized medicine. The ability to conduct genetic tests in-house allows hospitals to provide timely and accurate diagnoses, which are crucial for making informed treatment decisions, especially for patients with genetic conditions or complex diseases like cancer.

Hospitals are increasingly adopting gene panel testing to support their clinical decision-making processes. As the demand for personalized medicine grows, hospitals are investing in advanced diagnostic technologies, including gene panels, to better serve their patients. Moreover, the integration of gene panels into routine clinical practice is expected to continue growing, particularly in oncology and rare genetic disorders, where early and precise diagnosis can significantly improve patient outcomes. With the increasing availability of gene panels and the growing adoption of precision medicine, hospitals will continue to dominate the gene panel market.

North America Leads the Gene Panel Market

North America is the largest region in the gene panel market, driven by advanced healthcare infrastructure, significant research and development activities, and high healthcare expenditure. The United States, in particular, is a leader in genetic testing, with many biotech and pharmaceutical companies at the forefront of gene panel development and commercialization. The region benefits from a well-established regulatory environment, which facilitates the rapid adoption and use of advanced diagnostic tools such as gene panels. Furthermore, the increasing prevalence of genetic disorders, cancer, and chronic diseases in North America is fueling demand for more precise and personalized diagnostic solutions.

North America’s dominance in the gene panel market is also attributed to the high level of healthcare awareness and the growing acceptance of personalized medicine among both healthcare providers and patients. The presence of leading research institutions, clinical laboratories, and biopharmaceutical companies further strengthens the region's position in the market. With continued advancements in genomics and precision medicine, North America is expected to maintain its leadership in the global gene panel market for the foreseeable future.

Competitive Landscape and Leading Companies

The gene panel market is highly competitive, with numerous global and regional players actively engaged in the development, commercialization, and adoption of genetic testing technologies. Leading companies in the market include Thermo Fisher Scientific, Illumina, Agilent Technologies, Roche, and Bio-Rad Laboratories. These companies are at the forefront of gene panel technology development, offering a wide range of products tailored to different applications, from diagnostics to research and personalized medicine.

The competitive landscape is characterized by significant investments in research and development, as companies strive to innovate and improve the accuracy, efficiency, and affordability of gene panels. Partnerships and collaborations between biotechnology firms, academic institutions, and healthcare providers are common as stakeholders work together to enhance the capabilities of gene panels. As gene panel technologies continue to evolve, competition in the market will intensify, with companies focusing on improving panel performance, expanding their product offerings, and meeting the increasing demand for personalized and precision diagnostics.

List of Leading Companies:

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Qiagen N.V.
• Bio-Rad Laboratories, Inc.
• Roche Diagnostics
• PerkinElmer, Inc.
• Haplogen GmbH
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• Invitae Corporation
• MedGenome Labs
• Pacific Biosciences of California, Inc.
• Dante Labs
• Becton, Dickinson and Company (BD)

Recent Developments:

• In November 2024, Illumina, Inc. launched a new gene panel focused on hereditary cancer testing, improving the speed and accuracy of diagnosis.
• In October 2024, Thermo Fisher Scientific expanded its genetic testing portfolio with a new next-generation sequencing-based gene panel for rare genetic disorders.
• In September 2024, Roche Diagnostics announced the acquisition of a leading genetic testing company to enhance its offerings in gene panel diagnostics.
• In August 2024, Qiagen introduced a new PCR-based gene panel aimed at providing rapid detection of genetic mutations in infectious diseases.
• In July 2024, Myriad Genetics announced a partnership with major hospitals to expand its gene panel services in the oncology sector, offering personalized cancer treatment options.

Report Scope: